Clinical Trials Update

New Clinical Trials for Prostate, Kidney Cancers

Siteman Cancer Center has three new clinical trials open focused on prostate and kidney cancers. The first, a Phase II clinical trial testing a neoadjuvant immunotherapy treatment for prostate cancer, is available for men who have been diagnosed with localized prostate cancer. The study will evaluate the use of atezolizumab alone and in combination with […]

Novel Lymphoma Clinical Trials Underway

In just the past five years, the development of new therapeutics has changed the paradigm for the treatment of lymphomas, thereby improving outcomes and quality of life. As research continues, a major goal is to find more tolerable treatment options with higher efficacy. At Siteman Cancer Center, 35 open clinical trials are investigating novel immunotherapies, […]

Washington University to test ‘homegrown’ universal CAR T-cell therapy at Siteman Cancer Center

In early 2022, immunotherapy specialists at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine will begin a new clinical trial using off-the-shelf CAR T-cell therapy for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The therapy, developed by Washington University researchers at Siteman, incorporates many facets of the School […]

Think Clinical Trials after First Diagnosis

Advances in cancer care are happening every day. What’s the best way to find the latest treatment options available for your patients? Check for clinical trials. While many patients think clinical trials are for those who have exhausted all current standard-of-care (SoC) treatments for their type of cancer, the best time to consider participation in […]

Newly approved drug effective against lung cancer caused by genetic mutation

The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with […]